Metabolic Disorders
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Madrigal Has A Slow, Steady Launch Planned For Rezdiffra
Madrigal faces the challenge of opening the metabolic-associated steatohepatitis (MASH, also known as NASH) market, but the firm has been laying groundwork for over a year.
Bangers In MASH: How Rezdiffra's Rivals Stack Up
A look at the depth of clinical responses seen with various MASH therapies suggests that Madrigal could eventually face serious competition.
Ionis Could Be A Factor In MASH With Positive Phase II Data
Ionis’s DGAT2 inhibitor showed potential to improve disease activity score and resolve metabolic-associated steatohepatitis in a Phase II study, but analysts point to fibrosis-reduction data as competitively intriguing.
Sernova Seeks Cash And A Partner To Move Type 1 Diabetes Cell Therapy Forward
The company’s CEO Cynthia Pussinen joined the company last year and talked to Scrip about her plans to advance a cell therapy for type 1 diabetes.
Inventiva Gets OK To Resume Phase III MASH Study
Inventiva can resume screening and randomizing for its Phase III trial of lanifibranor in MASH, about three weeks after pausing the study due to a suspected unexpected serious adverse event.
Novo Nordisk Shows It Is Ready To Extend Its Obesity Portfolio
During a capital markets day, the company highlighted Phase I weight loss data for its novel oral obesity drug amycretin, which could work in a complementary fashion to GLP-1s.
Say Goodbye To NASH And Hello To MASH
The revised nomenclature of metabolic dysfunction-associated steatohepatitis (MASH), rather than non-alcoholic steatohepatitis (NASH), appears to be taking hold among stakeholders in the liver disease space.
Ozempic Cuts Kidney Risk By 24%
But Novo’s blockbuster lags established drugs in diabetic kidney disease patients, and will probably be regarded as an adjunct.
Akero’s 96-Week Fibrosis Data Sparkle In MASH
Akero’s Phase IIb study of FGF21 analog efruxifermin demonstrates long-term reduction or resolution of fibrosis, but concerns about bone mineral density declines may confound the data.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: optimistic outlook for biopharma IPOs; Boehringer’s promising MASH results; Viking emerges as obesity contender; Incyte looks to portfolio diversification; and a look at China’s HPV vaccine market.
Viking Emerges As Obesity Contender With Strong Phase II Readout
An analyst is calling data from Viking’s Phase II study of GLP-1/GIP agonist VK2735 best-in-class, even compared with approved therapies, with 13-week weight reductions as high as 14.7%.
Best-In-Class In MASH? Boehringer’s Hopes Raised By Glucagon/GLP-1 Phase II Results
The results could help BI and Zealand Pharma challenge in the MASH field, though analysts are wary of claims around fibrosis improvement.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.